Long-term outcomes of stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a multicentre, non-randomised, phase 2 study

The Lancet Oncology · Published 2026-05-17 · DOI 10.1016/s1470-2045(26)00091-4

Authors (28)

Shankar Siva, David Pryor, Jarad Martin, Nicholas Hardcastle, Daniel Moon, Tomas Kron, Braden Higgs, Farshad Foroudi, Jeremy Ruben, Swetha Sridharan, Rebecca Montgomery, Ryan Davey, Charles Lin, Mark Shaw, Nathan Lawrentschuk, Sree Appu, Ben G L Vanneste, Michael S Hofman, Declan G Murphy, Richard De Abreu Lourenco, Pascal Mancuso, Nicholas R Brook, Avi Raman, Lih-Ming Wong, Mark Sidhom, Simon Wood, Muhammad Ali, Mathias Bressel

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2026

Citation

Siva, S., Pryor, D., Martin, J., et al. (2026). Long-term outcomes of stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a multicentre, non-randomised, phase 2 study. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(26)00091-4

Related articles